The American Gastroenterological Association has issued new clinical guidance on gastroparesis, emphasizing a personalized, patient-centered approach over rigid treatment pathways. The guideline includes 12 conditional recommendations shaped by both clinical evidence and patient input.
Key updates include the preference for a four-hour gastric emptying scintigraphy study (over shorter ≤2-hour protocols) for accurate diagnosis, and metoclopramide or erythromycin as first-line pharmacologic options. Beyond medication, the guidance urges shared decision-making, highlights unmet needs, and calls for innovation to expand treatment options for this challenging condition.